Jane Purser, MD
Payments from drug & device makers
Across 407 payments — averaging $40.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharming Healthcare, Inc.$6K
- Genentech USA, Inc.$1K
- AstraZeneca$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- CSL Behring$1K
- Regeneron Healthcare Solutions, Inc.$835
- plus $5K from 23 others
What the payments were for
- Consulting fees$4,37527%
- Travel & lodging$1,4049%
- Food & beverage$10,21162%
- Education$3752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharming Healthcare, Inc. | 30 | $5,750 |
| Genentech USA, Inc. | 54 | $1,397 |
| AstraZeneca | 40 | $1,293 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $1,179 |
| CSL Behring | 43 | $1,029 |
| Regeneron Healthcare Solutions, Inc. | 31 | $835 |
| Biocryst US Sales Co., LLC | 20 | $623 |
| Sanofi | 22 | $595 |
| GSK | 31 | $535 |
| Alk-abello, Inc | 15 | $517 |
| Genentech, Inc. | 8 | $407 |
| Novartis | 16 | $309 |
| Pfizer | 10 | $299 |
| Blueprint Medicines Corporation | 11 | $250 |
| Shire North American Group Inc | 13 | $230 |
| Sanofi-aventis U.S. LLC | 3 | $189 |
| Amgen | 3 | $178 |
| Optinose US, Inc. | 9 | $169 |
| Grifols USA, LLC | 7 | $104 |
| Kaleo, Inc. | 6 | $92 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $70 |
| Boehringer Ingelheim | 3 | $70 |
| Mylan Specialty L.p. | 3 | $64 |
| Greer Laboratories, Inc. | 4 | $58 |
| Galderma Laboratories, L.p. | 2 | $48 |
| AbbVie | 1 | $31 |
| Merck | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RuconestC1 Esterase Inhibitor, Recomb | 23 | $4,438,521 |
| BerinertC1 Esterase Inhibitor | 65 | $1,442,464 |
| Dupixent PenDupilumab | 44 | $173,715 |
| NucalaMepolizumab | 12 | $135,450 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 109 | $106,491 |
| Breo ElliptaFluticasone/Vilanterol | 148 | $89,222 |
| Dupixent SyringeDupilumab | 11 | $40,411 |
| Spiriva RespimatTiotropium Bromide | 28 | $20,756 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $15,499 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $14,617 |
| DuleraMometasone/Formoterol | 21 | $13,428 |
| Arnuity ElliptaFluticasone Furoate | 33 | $13,298 |
| XhanceFluticasone Propionate | 21 | $12,713 |
| Epinephrine | 62 | $11,151 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $10,633 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharming Healthcare, Inc.Ruconest | $5,750 | $4,438,52123 claims |
| CSL BehringBerinert | $1,029 | $1,442,46465 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $535 | $344,460302 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $1,293 | $30,11654 claims |
| Boehringer IngelheimSpiriva Respimat | $70 | $20,75628 claims |
| MerckDulera | $19 | $13,42821 claims |
| Optinose US, Inc.Xhance | $169 | $12,71321 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $11 | $3,83013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other allergy in Tulsa
- Timothy NickelTulsa$51K
- Lodie NaimehTulsa$7K
- James LoveTulsa$7K
- Martha TarpayOklahoma City$6.3M
- Claire AtkinsonOklahoma City$9K
- Gregory MetzOklahoma City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.